Compare Novo Nordisk A/S (NVO) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Veritone Inc — how do they compare? Novo Nordisk A/S trades at $45.01 (market cap $198.57B), while Veritone Inc trades at $0.87 (market cap $85.83M). The key difference: Novo Nordisk A/S is far larger — about 2313.5× Veritone Inc's market cap, and Novo Nordisk A/S pays a 4.03% dividend while Veritone Inc pays none. Which is the better fit depends on your goals.
| NVO | VERI | |
|---|---|---|
Market Cap | $198.57B | $85.83M |
Sector | Health | Technology |
52-Week High | $63.98 | $8.39 |
52-Week Low | $35.29 | $0.79 |
Enterprise Value | $213.37B | $121.22M |
Dividend Yield | 4.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
Veritone (VERI) trades at $0.9155, up 0.99% on the day, amid a bearish technical signal and negative earnings trends. The company reported a net loss of $111.73 million in 2025, with revenue of $92.19 million, and has missed earnings expectations in recent quarters. Recent news includes a securities class action investigation and partnerships to expand AI solutions.
Outlook remains challenged by persistent losses and legal overhangs, though cost reduction efforts and AI partnerships offer potential growth. Investment risks include high cash burn, negative margins, and shareholder litigation. Analyst sentiment is mixed with a slight buy bias, but fundamental weakness limits near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
